ImmuPharma (GB:IMM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuPharma PLC, a biopharmaceutical company focusing on peptide-based therapeutics, has announced its Annual General Meeting (AGM) to be held on June 28, 2024. Shareholders are informed that the AGM details and Annual Report for 2023 are available on the company’s website. The company specializes in developing treatments for autoimmune diseases, with its leading program, P140, showing promise for Lupus and other autoimmune disorders.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.